Five Chinese Biotechs Tap IPOs To Study First-In-Class Candidates Overseas

Multiple Hong Kong Listings Planned

 
• By Dexter Jie Yan
  
IPO
Since the end of 2025, at least five Chinese biotechs have filed IPO applications to support overseas clinical development of first-in-class molecules. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D